Abstract:Objective To evaluate the clinical curative effect and safety of different doses of calf pulmonary surfactant in the treatment of premature infants with respiratory distress syndrome. Methods The premature infants with respiratory distress syndrome were treated with three different doses of calf pulmonary surfactant. 93 cases met the inclusive criteria among the whole cases. There were 31 cases treated with small doses of calf pulmonary surfac-tant (40-70mg/kg), 31 cases treated with middle doses of calf pulmonary surfactant (70-100 mg/kg) and 31 ca-ses treated with large doses of calf pulmonary surfactant (100-140mg/kg). The results of blood gas analysis were compared among the three groups before and after treatment, including pH, arterial oxygen tension and arterial carbon oxygen tension. Other items of comparison included sex, gestational age, birth weight, cesarean section, Apgar scores, amniotic fluid, need for repeated drug use, need for mechanical ventilation, duration of mechanical ventila-tion, duration of oxygen therapy, duration of hospital stay, outcomes, complications and average hospital expenses. Results There was no significant difference in sex, gestational age, birth weight, cesarean section, Apgar scores, amniotic fluid and premature rupture of membranes among the three groups (P>0. 05). 6 hours after the first appli-cation of pulmonary surfactant, the pH value and the arterial oxygen tension of the whole infants increased in varying degrees, and the arterial carbon oxygen tension of the whole infants decreased in varying degrees ( P<0. 05 ) . The differences of pH value, arterial oxygen tension and arterial carbon oxygen tension among the three groups had no sta-tistical significance before the treatment ( P >0. 05 ) . The difference of the curative effect among the three groups ( including the need for repeated drug use, the need for mechanical ventilation, the duration of mechanical ventilation and the duration of oxygen therapy) had no statistical significance (P>0. 05). There was no significant difference in complication morbidity and the cure rate among the three groups (P>0. 05), but it showed significant differences in the average hospital expenses and the average duration of hospital stay among the three groups ( P<0. 05 ) . Com-pared with the large dose group, the average hospital expenses in the middle dose group decreased. And compared with the small dose group, the average duration of hospital stay in the middle dose group decreased. Conclusion The clinical curative effect and safety of the three doses of calf pulmonary surfactant are analogous in the treatment of premature infants with respiratory distress syndrome. But the average hospitalization expenses in the middle doses group is less than that of the large doses groups, and the average duration of hospitalization in the middle dose group is less than that of the small doses group.

Comparison of the effect of Calsurf and Curosurf in treating respiratory distress syndrome of preterm infants

Observation on the Clinical Curative Effect of Different Doses of Calf Pulmonary Surfactant in the Treatment of Premature Infants with Respiratory Distress Syndrome

In Vitro Characterization and in Vivo Comparison of the Pulmonary Outcomes of Poractant Alfa and Calsurf in Ventilated Preterm Rabbits

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

The Oberservation of Effect of Pulmonary Surfactant on Preterm Infant's Respiratory Distress Syndrome

Comparative Study for Influence on Neonatal Respiratory Distress Syndrome between Different Pulmonary Surfactants

Beneficial effect of exogenous pulmonary surfactant in infants suffering acute respiratory distress syndrome after cardiac surgery

Beneficial Effect of Exogenous Surfactant in Infants Suffering Acute Respiratory Distress Syndrome after Cardiac Surgery.

Rescue Treatment of Neonatal Respiratory Distress Syndrome

Analysis on Clinical Efficacy of Different Doses of Pulmonary Surfactant Administrated in Different Time for the Treatment of NRDS

Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome

Nasal continuous positive airway pressure versus pulmonary surfactant in prevention of neonatal respiratory distress syndrome

Curosurf Combined w ith Bilevel Positive Airw ay Pressure Ventilation to Prevent Premature Infants with Respiratory Distress Syndrome Observation of Clinical Curative Effect

Effect of continuous positive airway pressure ventilation combined with bovine alveolar surfactant on cerebral oxygen metabolism in neonates with respiratory distress syndrome

The impact of surfactant replacement therapy on cerebral and systemic circulation and lung function

Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits

Effect of low-dose exogenous surfactant on infants with acute respiratory distress syndrome after cardiac surgery: a retrospective analysis

Influence of Inhaled Ambroxol Hydrochloride and Budesonide Suspension on Partial Pressure of Oxygen and Partial Pressure of Carbon Dioxide of Premature

Prophylaxis of Neonatal Respiratory Distress Syndrome by Intra-Amniotic Administration of Pulmonary Surfactant.

Comparing the Effects of Two Surfactant Administration Methods: Minimally Invasive Surfactant Therapy (MIST) with Intubation (INSURE) in Infants with Respiratory Distress Syndrome

DuoPAP combined with InSurE in treatment of premature infants with respiratory distress syndrome